MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis
Jiaofeng Huang,1,* Wenjuan Xue,2,* Mingfang Wang,1 Yinlian Wu,1 Medha Singh,3 Yueyong Zhu,1,4 Rahul Kumar,5 Su Lin1 1Department of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, 350005, People’s Republic of China;...
Enregistré dans:
Auteurs principaux: | Huang J, Xue W, Wang M, Wu Y, Singh M, Zhu Y, Kumar R, Lin S |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/d35b26b12fbc41f3b38e6c86900e9672 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Biochanin A Regulates Cholesterol Metabolism Further Delays the Progression of Nonalcoholic Fatty Liver Disease
par: Fan Y, et autres
Publié: (2021) -
Liver biopsy in the quantitative assessment of liver fibrosis in nonalcoholic fatty liver disease
par: Gwyneth Shook Ting Soon, et autres
Publié: (2021) -
Serum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort
par: Cao W, et autres
Publié: (2021) -
Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis
par: Filip R, et autres
Publié: (2018) -
Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases
par: Jorge Gutiérrez-Cuevas, et autres
Publié: (2021)